What were the primary drivers of revenue growth in this quarter?

Revenue growth was primarily driven by the Pharmaceutical Distribution segment, which saw a 12% increase in operating revenue. This growth was attributed to increased sales to institutional customers, the conversion of bulk delivery business to operating revenue, and the expansion of the specialty pharmaceutical business. Acquisitions also contributed to revenue, though a smaller percentage in this period.

How did recent acquisitions impact the company's financial position?

Recent acquisitions, such as Anderson Packaging, US Bioservices, and Bridge Medical, have increased goodwill by $181 million, bringing the total to $2.39 billion. These acquisitions also contributed to the overall revenue growth and are expected to enhance the company's service offerings, particularly in specialty pharmaceuticals and packaging. The purchase prices for these acquisitions were funded through a combination of cash and newly issued common stock.

What is the company's current debt situation and how is it being managed?

Total debt increased to $2.3 billion as of June 30, 2003. This increase is due to new debt issuances, including $300 million in 7.25% senior notes, and increased borrowings under revolving credit and securitization facilities. The company manages its debt by maintaining a mix of fixed-rate and variable-rate debt, and has recently entered into a new, larger receivables securitization facility to optimize financing costs.

What is the reason for the significant cash used in operating activities for the nine months ended June 30, 2003?

The primary reason for the $792.4 million cash used in operating activities for the nine-month period was a substantial increase in merchandise inventories ($1.27 billion) and accounts receivable ($249 million). This increase in inventory was partly to support revenue growth and take advantage of purchasing opportunities, but also due to holding duplicative inventory during facility consolidation. While net income was positive, these working capital changes significantly impacted operating cash flow.

COR 10-Q Quarterly Report Q3 FY2003 — Revenue, Net Income, EPS

Summary

AmerisourceBergen Corporation (COR) reported solid financial results for the fiscal quarter ended June 30, 2003. The company saw a notable increase in operating revenue, driven primarily by its Pharmaceutical Distribution segment. Net income and diluted earnings per share also showed significant year-over-year growth. The company has actively pursued strategic acquisitions during the period, including Anderson Packaging Inc., US Bioservices Corporation, and Bridge Medical, Inc., which are expected to enhance its service offerings and market position. Despite revenue growth and improved profitability, the company is managing increased inventory levels, which impacted operating cash flow. However, a robust financing structure, including revolving credit and receivables securitization facilities, provides ample liquidity. The company continues its integration efforts post-merger, aiming for cost synergies, which are contributing to operational efficiencies. Investors should note the ongoing integration activities and the company's strategy of expanding its specialty pharmaceutical and packaging services through targeted acquisitions.

Key Highlights

1Operating revenue increased by 12% to $11.5 billion for the quarter ended June 30, 2003, compared to $10.3 billion in the prior-year quarter.
2Net income rose 25% to $112.5 million for the quarter, with diluted earnings per share increasing to $0.99 from $0.82.
3The company completed several key acquisitions: Anderson Packaging Inc., US Bioservices Corporation, and Bridge Medical, Inc., to expand service offerings.
4Goodwill increased significantly due to acquisitions, reaching $2.39 billion.
5Long-term debt increased by approximately $482 million to $2.24 billion, reflecting increased borrowings and the issuance of new senior notes.
6Cash used in operating activities for the nine months ended June 30, 2003 was $(792.4) million, primarily due to a significant increase in merchandise inventories and accounts receivable.
7The company continues its merger integration plans, aiming for approximately $150 million in annual synergies by the end of fiscal 2004.

Cencora, Inc. Quarterly Report for Q3 Ended Jun 30, 2003

Summary

Key Highlights

Frequently Asked Questions